Human Molecular Genetics Advance Access published online on February 17, 2005
Human Molecular Genetics, doi:10.1093/hmg/ddi086
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Institute of Biomedical and Clinical Science, Peninsula Medical School, Exeter, EX2 5DW, UK; Diabetes Research Laboratories, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, OX3 7LJ, UK
* To whom correspondence should be addressed. Neonatal diabetes can either remit and hence be transient or else may be permanent. These two phenotypes were considered to be genetically distinct. Abnormalities of 6q24 are the commonest cause of transient neonatal diabetes (TNDM). Mutations in KCNJ11, which encodes Kir6.2, the pore forming subunit of the ATP-sensitive potassium channel (KATP), are the commonest cause of permanent neonatal diabetes (PNDM). Some KCNJ11 mutations result in marked developmental delay and epilepsy in addition to diabetes. These mutations are more severe on functional characterisation. We investigated whether mutations in KCNJ11 could also give rise to transient neonatal diabetes (TNDM). We identified 3 novel heterozygous mutations (G53S, G53R, I182V) in 3 of 11 probands with clinically defined TNDM who did not have chromosome 6q24 abnormalities. The mutations co-segregated with diabetes within families and were not found in 100 controls. All probands had insulin treated diabetes diagnosed in the first four months and went into remission by 7-14 months. Functional characterisation of the TNDM associated mutations was performed by expressing the mutated Kir6.2 with SUR1 in Xenopus laevis oocytes. All 3 heterozygous mutations resulted in a reduction in the sensitivity to ATP compared to wild type (IC50
Article
Relapsing diabetes can result from moderately activating mutations in KCNJ11
2 Cambridge Institute for Medical Research, University of Cambridge, Wellcome Trust/MRC building, Hills Road, Cambridge, CB2 2XY, UK
3 University Laboratory of Physiology, University of Oxford, OX1 4TP, UK
4 Institute of Biomedical and Clinical Science, Peninsula Medical School, Exeter, EX2 5DW, UK
5 Wessex Clinical Genetics Service, NHS Trust, Southampton, S016 5YA, UK; Division of Human Genetics, Southampton University, Salisbury, SO16 6YD, UK
6 Division of Human Genetics, Southampton University, Salisbury, SO16 6YD, UK; Wessex Regional Genetics Labs, Salisbury District Hospital, Salisbury, SP2 8BJ, UK
7 The Royal Hospital for Children, Bristol, BS2 8AE, UK
8 Genetics Institute of Austin, Texas Department of Health, Austin, Texas, TX 78705, USA
9 Department of Diabetes Endocrinology & Diabetes, The Royal Hospital for Sick Children, Edinburgh, EH9 1LF, UK
10 Institute of Biomedical and Clinical Science, Peninsula Medical School, RD & E Hospital (Wonford), Barrack Road, Exeter, EX2 5DW, UK
Andrew T. Hattersley, E-mail: A.T.Hattersley{at}exeter.ac.uk
![]()
Abstract
30 vs
7 µM, p all <0.01), however this was less profoundly reduced than with the PNDM associated mutations. In conclusion, mutations in KCNJ11 are the first genetic cause for remitting as well as permanent diabetes. This suggests a fixed ion channel abnormality can result in a fluctuating glycaemic phenotype. The multiple phenotypes associated with activating KCNJ11 mutations may reflect their severity in vitro.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. Aguilar-Bryan and J. Bryan Neonatal Diabetes Mellitus Endocr. Rev., May 1, 2008; 29(3): 265 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Koster, F. Cadario, C. Peruzzi, C. Colombo, C. G. Nichols, and F. Barbetti The G53D Mutation in Kir6.2 (KCNJ11) Is Associated with Neonatal Diabetes and Motor Dysfunction in Adulthood that Is Improved with Sulfonylurea Therapy J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 1054 - 1061. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Burke, R. K. Mutharasan, and H. Ardehali The Sulfonylurea Receptor, an Atypical ATP-Binding Cassette Protein, and Its Regulation of the KATP Channel Circ. Res., February 1, 2008; 102(2): 164 - 176. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P.H. Shield, S. E. Flanagan, D. J. Mackay, L. W. Harries, P. Proks, C. Girard, F. M. Ashcroft, I. K. Temple, and S. Ellard Mosaic Paternal Uniparental Isodisomy and an ABCC8 Gene Mutation in a Patient With Permanent Neonatal Diabetes and Hemihypertrophy Diabetes, January 1, 2008; 57(1): 255 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Polak Neonatal Diabetes Mellitus: Insights for More Common Forms of Diabetes J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3774 - 3776. [Full Text] [PDF] |
||||
![]() |
S. Suzuki, Y. Makita, T. Mukai, K. Matsuo, O. Ueda, and K. Fujieda Molecular Basis of Neonatal Diabetes in Japanese Patients J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3979 - 3985. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Flanagan, A.-M. Patch, D. J.G. Mackay, E. L. Edghill, A. L. Gloyn, D. Robinson, J. P.H. Shield, K. Temple, S. Ellard, and A. T. Hattersley Mutations in ATP-Sensitive K+ Channel Genes Cause Transient Neonatal Diabetes and Permanent Diabetes in Childhood or Adulthood Diabetes, July 1, 2007; 56(7): 1930 - 1937. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B Nielsen, K. B Ploug, P. Swift, C. Orskov, I. Jansen-Olesen, F. Chiarelli, J. J Holst, P. Hougaard, S. Porksen, R. Holl, et al. Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes Eur. J. Endocrinol., June 1, 2007; 156(6): 663 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Vaxillaire, A. Dechaume, K. Busiah, H. Cave, S. Pereira, R. Scharfmann, G. P. de Nanclares, L. Castano, P. Froguel, M. Polak, et al. New ABCC8 Mutations in Relapsing Neonatal Diabetes and Clinical Features Diabetes, June 1, 2007; 56(6): 1737 - 1741. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Edghill, A. L. Gloyn, A. Goriely, L. W. Harries, S. E. Flanagan, J. Rankin, A. T. Hattersley, and S. Ellard Origin of de Novo KCNJ11 Mutations and Risk of Neonatal Diabetes for Subsequent Siblings J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1773 - 1777. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Stanik, D. Gasperikova, M. Paskova, L. Barak, J. Javorkova, E. Jancova, M. Ciljakova, P. Hlava, J. Michalek, S. E. Flanagan, et al. Prevalence of Permanent Neonatal Diabetes in Slovakia and Successful Replacement of Insulin with Sulfonylurea Therapy in KCNJ11 and ABCC8 Mutation Carriers J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1276 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Masia, J. C. Koster, S. Tumini, F. Chiarelli, C. Colombo, C. G. Nichols, and F. Barbetti An ATP-Binding Mutation (G334D) in KCNJ11 Is Associated With a Sulfonylurea-Insensitive Form of Developmental Delay, Epilepsy, and Neonatal Diabetes Diabetes, February 1, 2007; 56(2): 328 - 336. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Diatloff-Zito, A Nicole, G Marcelin, H Labit, E Marquis, C Bellanne-Chantelot, and J J Robert Genetic and epigenetic defects at the 6q24 imprinted locus in a cohort of 13 patients with transient neonatal diabetes: new hypothesis raised by the finding of a unique case with hemizygotic deletion in the critical region J. Med. Genet., January 1, 2007; 44(1): 31 - 37. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Koster, M. S. Remedi, R. Masia, B. Patton, A. Tong, and C. G. Nichols Expression of ATP-Insensitive KATP Channels in Pancreatic {beta}-Cells Underlies a Spectrum of Diabetic Phenotypes Diabetes, November 1, 2006; 55(11): 2957 - 2964. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. I. Tarasov, H. J. Welters, S. Senkel, G. U. Ryffel, A. T. Hattersley, N. G. Morgan, and F. M. Ashcroft A Kir6.2 Mutation Causing Neonatal Diabetes Impairs Electrical Activity and Insulin Secretion From INS-1 {beta}-Cells Diabetes, November 1, 2006; 55(11): 3075 - 3082. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Pearson, I. Flechtner, P. R. Njolstad, M. T. Malecki, S. E. Flanagan, B. Larkin, F. M. Ashcroft, I. Klimes, E. Codner, V. Iotova, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med., August 3, 2006; 355(5): 467 - 477. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Slingerland and A. T. Hattersley Activating Mutations in the Gene Encoding Kir6.2 Alter Fetal and Postnatal Growth and Also Cause Neonatal Diabetes J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2782 - 2788. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Proks, A. L. Arnold, J. Bruining, C. Girard, S. E. Flanagan, B. Larkin, K. Colclough, A. T. Hattersley, F. M. Ashcroft, and S. Ellard A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes Hum. Mol. Genet., June 1, 2006; 15(11): 1793 - 1800. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Shimomura, C. A.J. Girard, P. Proks, J. Nazim, J. D. Lippiat, F. Cerutti, R. Lorini, S. Ellard, A. T. Hattersley, F. Barbetti, et al. Mutations at the Same Residue (R50) of Kir6.2 (KCNJ11) That Cause Neonatal Diabetes Produce Different Functional Effects Diabetes, June 1, 2006; 55(6): 1705 - 1712. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Proks, C. Girard, H. Baevre, P. R. Njolstad, and F. M. Ashcroft Functional Effects of Mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), Causing Neonatal Diabetes, and Response to Sulfonylurea Therapy Diabetes, June 1, 2006; 55(6): 1731 - 1737. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-W. Lin, Y.-W. Lin, F.-F. Yan, J. Casey, M. Kochhar, E. B. Pratt, and S.-L. Shyng Kir6.2 Mutations Associated With Neonatal Diabetes Reduce Expression of ATP-Sensitive K+ channels: Implications in Disease Mechanism and Sulfonylurea Therapy Diabetes, June 1, 2006; 55(6): 1738 - 1746. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Hattersley and E. R. Pearson Minireview: Pharmacogenetics and Beyond: The Interaction of Therapeutic Response, {beta}-Cell Physiology, and Genetics in Diabetes Endocrinology, June 1, 2006; 147(6): 2657 - 2663. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Koster, M. A. Permutt, and C. G. Nichols Diabetes and Insulin Secretion: The ATP-Sensitive K+ Channel (KATP) Connection Diabetes, November 1, 2005; 54(11): 3065 - 3072. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Remedi, J. C. Koster, B. L. Patton, and C. G. Nichols ATP-Sensitive K+ Channel Signaling in Glucokinase-Deficient Diabetes Diabetes, October 1, 2005; 54(10): 2925 - 2931. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Proks, C. Girard, and F. M. Ashcroft Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP Hum. Mol. Genet., September 15, 2005; 14(18): 2717 - 2726. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Hattersley and F. M. Ashcroft Activating Mutations in Kir6.2 and Neonatal Diabetes: New Clinical Syndromes, New Scientific Insights, and New Therapy Diabetes, September 1, 2005; 54(9): 2503 - 2513. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Koster, M. S. Remedi, C. Dao, and C. G. Nichols ATP and Sulfonylurea Sensitivity of Mutant ATP-Sensitive K+ Channels in Neonatal Diabetes: Implications for Pharmacogenomic Therapy Diabetes, September 1, 2005; 54(9): 2645 - 2654. [Abstract] [Full Text] [PDF] |
||||








